

Assoc. Prof. ZAFER ARIK

Personal Information

Office Phone: [+90 312 305 2929](tel:+903123052929) Extension: 2929

Email: zafer.arik@hacettepe.edu.tr

Education Information

Post Doctorate of Medicine, Hacettepe Üniversitesi, Tıp Fakültesi, İç Hastalıkları Anabilim Dalı Medikal Onkoloji Bilim Dalı, Turkey 2011 - 2013

Expertise In Medicine, Hacettepe Üniversitesi, Tıp Fakültesi, İç Hastalıkları, Turkey 2004 - 2010

Undergraduate, Hacettepe Üniversitesi, Tıp Fakültesi (ingilizce), Turkey 1997 - 2004

Foreign Languages

English, B2 Upper Intermediate

Dissertations

Expertise In Medicine, HACETTEPE ÜNİVERSİTESİ HASTANELERİ'NDE TAKİP EDİLEN METASTATİK RENAL HÜCRELİ KANSER HASTALARININ SAĞKALIMLARININ ZAMAN İÇİNDE DEĞİŞİMİNİN İNCELENMESİ, Hacettepe Üniversitesi, Tıp Fakültesi, İç Hastalıkları Medikal Onkoloji, 2013

Expertise In Medicine, ZOLEDRONİK ASİDİN RATLARDA DOKU SDF-1 EKSPRESYONU ÜZERİNDEKİ ETKİSİ, Hacettepe Üniversitesi, Tıp Fakültesi, İç Hastalıkları, 2010

Research Areas

Medicine, Health Sciences, Internal Medicine Sciences, Internal Diseases , Oncology

Academic Titles / Tasks

Assistant Professor, Hacettepe Üniversitesi, Tıp Fakültesi, İç Hastalıkları, 2017 - Continues

Articles Published in Journals That Entered SCI, SSCI and AHCI Indexes

- Newly diagnosed cancer and the COVID-19 pandemic: tumour stage migration and higher early mortality**
GÜVEN D. C. , ŞAHİN T. K. , YILDIRIM H. Ç. , ÇEŞMECİ E., İncesu F. G. G. , TAHILLIOĞLU Y., ÜÇGÜL E., AKSUN M. S. , GÜRBÜZ S. Ç. , AKTEPE O. H. , et al.
BMJ SUPPORTIVE & PALLIATIVE CARE, 2021 (Journal Indexed in SCI)
- Lesson learned from the pandemic: Isolation and hygiene measures for COVID-19 could reduce the nosocomial infection rates in oncology wards**
GÜVEN D. C. , EROĞLU İ., İsmayilov R., ULUSOYDAN E., AKTEPE O. H. , TELLİ DİZMAN G., ARIK Z., DİZDAR Ö., ÜNAL

S., METAN G., et al.

JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2021 (Journal Indexed in SCI)

- III. **Comparison of weekly methotrexate regimen versus methotrexate folinic acid 8-day regimen for treatment of low-risk gestational trophoblastic neoplasia**
Korkmaz V., Sunar V., Akar S., Alinca C. M. , ARIK Z., Boran N., Ozdal B., Ustun Y. E.
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2021 (Journal Indexed in SCI)
- IV. **The prognostic significance of microsatellite status and its relationship with tumor-infiltrating lymphocyte in endometrial cancer**
Lacin S., TAŞAR KAPAKLI G. E. , USUBÜTÜN A., ARIK Z., YÜCE D., SALMAN M. C. , Kars A.
EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY, vol.42, no.3, pp.541-547, 2021 (Journal Indexed in SCI)
- V. **Poorer baseline performance status is associated with increased thromboembolism risk in metastatic cancer patients treated with immunotherapy**
GÜVEN D. C. , AKSUN M. S. , ŞAHİN T. K. , AKTEPE O. H. , YILDIRIM H. Ç. , TABAN H., Ceylan F., KERTMEN N., ARIK Z., DİZDAR Ö., et al.
SUPPORTIVE CARE IN CANCER, 2021 (Journal Indexed in SCI)
- VI. **Frequency of germline BRCA1/2 mutations and association with clinicopathological characteristics in Turkish women with epithelial ovarian cancer**
Sunar V., Korkmaz V., Topcu V., Cavdarli B., ARIK Z., Ozdal B., Ustun Y. E.
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2021 (Journal Indexed in SCI)
- VII. **Comparison of Efficacies of Dose Dense Paclitaxel Plus Carboplatin and Conventional Paclitaxel Plus Carboplatin in the Treatment of Epithelial Ovarian Cancer**
Sunar V., Korkmaz V., Aslan K., Kose C., Sarici F., ARIK Z., Meydanli M. M.
UHOD-ULUSLARARASI HEMATOLOJİ-ONKOLOJİ DERGİSİ, vol.31, no.4, pp.239-245, 2021 (Journal Indexed in SCI)
- VIII. **Perspectives, fears and expectations of patients with gynaecological cancers during the COVID-19 pandemic: A Pan-European study of the European Network of Gynaecological Cancer Advocacy Groups (ENGAGe)**
GÜLTEKİN M., AK S., AYHAN A., Strojna A., Pletnev A., Fagotti A., Perrone A. M. , ERZENEÖĞLU B. E. , TEMİZ B. E. , Lemley B., et al.
CANCER MEDICINE, 2020 (Journal Indexed in SCI)
- IX. **Defining the Optimal Regimen for Stage III Colon Cancer: Concerns with Study Design**
GÜVEN D. C. , GÜNER G., AKTAŞ B. Y. , AKTEPE O. H. , TABAN H., ARIK Z.
CLINICAL COLORECTAL CANCER, vol.19, no.3, 2020 (Journal Indexed in SCI)
- X. **Multi-institutional validation of the ESMO-ESGO-ESTRO consensus conference risk grouping in Turkish endometrial cancer patients treated with comprehensive surgical staging**
GÜLTEKİN M., Guler O. C. , Sari S., Yildirim B. A. , Onal C., Celik H., Yuce K., Ayhan A., ARIK Z., Kose F., et al.
JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 2020 (Journal Indexed in SCI)
- XI. **Efficacy of Pazopanib in patients with metastatic uterine sarcoma: A multi-institutional study**
Sunar V., Korkmaz V., AKIN S., GÜVEN D. C. , ARIK Z., Ates O., Yilmaz M., Meydanli M. M. , Oksuzoglu B.
JOURNAL OF BUON, vol.24, no.6, pp.2327-2332, 2019 (Journal Indexed in SCI)
- XII. **Retrospective Analysis of Gestational Trophoblastic Neoplasia: Single Center Experience**
Sunar V., Korkmaz V., ARIK Z., Ozdal B., Engin Ustun Y.
UHOD-ULUSLARARASI HEMATOLOJİ-ONKOLOJİ DERGİSİ, vol.29, no.3, pp.168-175, 2019 (Journal Indexed in SCI)
- XIII. **Cytoreductive Surgery for Intestinal Cancer Patients Metastatic to Ovaries Presenting as Primary Ovarian Cancer**
Arik Z., Oz M., DİZDAR Ö., YILDIRIM M. E. , OZGU E., TERZIOĞLU S. G. , GUNGOR T.
UHOD-ULUSLARARASI HEMATOLOJİ-ONKOLOJİ DERGİSİ, vol.26, no.2, pp.110-115, 2016 (Journal Indexed in SCI)
- XIV. **Molecular subtypes in patients with inflammatory breast cancer; A single center experience**
KERTMEN N., BABACAN T., Keskin O., Solak M., Sarici F., AKIN S., ARIK Z., Aslan A., ATEŞ Ö., AKSOY S., et al.
JOURNAL OF BUON, vol.20, no.1, pp.35-39, 2015 (Journal Indexed in SCI)
- XV. **A systemic late recurrence after the first operation in a patient diagnosed with early-stage breast cancer: the latest recurrence in the literature**

- Keskin O. D. , KERTMEN N., Karakas Y., BABACAN T., ARIK Z., Altundag K., Gullu I.
JOURNAL OF BUON, vol.20, no.1, pp.348, 2015 (Journal Indexed in SCI)
- XVI. **Evaluation of the effect of comorbidity on survival in pancreatic cancer by using "Charlson Comorbidity Index" and "Cumulative Illness Rating Scale"**
Kos F. T. , Yazici O., Civelek B., Seker M., ARIK Z., AKSOY S., Uncu D., Ozdemir N., Zengin N.
WIENER KLINISCHE WOCHENSCHRIFT, vol.126, pp.36-41, 2014 (Journal Indexed in SCI)
- XVII. **Association between common risk factors and molecular subtypes in breast cancer patients**
Turkoz F. P. , Solak M., Petekkaya I., Keskin O., KERTMEN N., Sarici F., ARIK Z., BABACAN T., Ozisik Y., Altundag K.
BREAST, vol.22, no.3, pp.344-350, 2013 (Journal Indexed in SCI)
- XVIII. **Demographic and clinico-pathological characteristics of breast cancer patients with history of oral alendronate use**
Sendur M. A. N. , Aksoy S., Yaman S., Arik Z., Ozdemir N. Y. , Zengin N., Altundag K.
MEDICAL ONCOLOGY, vol.29, no.4, pp.2601-2605, 2012 (Journal Indexed in SCI)
- XIX. **Dermatomyositis complicated with a soft tissue sarcoma**
Sendur M. A. N. , Aksoy S., Yaman S., Arik Z., Kilinc L., Zengin N.
RHEUMATOLOGY INTERNATIONAL, vol.32, no.10, pp.3329-3330, 2012 (Journal Indexed in SCI)
- XX. **Can all beta blockers improve the breast cancer survival?**
Sendur M. A. N. , Aksor S., Yaman S., Arik Z., Altundag K.
BREAST, vol.21, no.1, pp.107-108, 2012 (Journal Indexed in SCI)
- XXI. **Is There an Association between Blood Group and Survival in Pancreatic Cancer?**
Kos F. T. , Civelek B., Seker M. M. , ARIK Z., AKSOY S., Uncu D., Ozdemir N., Zengin N.
ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, vol.13, no.12, pp.6151-6153, 2012 (Journal Indexed in SCI)
- XXII. **Breast Cancer in a Patient with Agnogenic Myeloid Metaplasia**
ARIK Z., OZKAN C., Ozdemir E., ALTUNDAG K.
SOUTHERN MEDICAL JOURNAL, vol.103, no.10, pp.1075-1076, 2010 (Journal Indexed in SCI)

Books & Book Chapters

- I. **Kastrasyona dirençli prostat kanseri tedavisi**
ERMAN M., ARIK Z.
in: Üroonkoloji Kitabı, , Editor, Nobel, 2018

Refereed Congress / Symposium Publications in Proceedings

- I. **Embedded outpatient palliative care service within the oncology clinic: Preliminary experience in Hacettepe Oncology Hospital**
Güven D. C. , AKTEPE O. H. , Berk Z., Guner G., Taban H., AKTAŞ B. Y. , Duran Z. C. , AKIN Ş., ARIK Z., KERTMEN N., et al.
44th Congress of the European-Society-for-Medical-Oncology (ESMO), Barcelona, Spain, 27 September - 01 October 2019, vol.30
- II. **Clinicopathologic features of BRCA mutated breast cancer patients: Hacettepe experience**
AKSOY S., DEĞİRMENCİLER R. F. , AKTAŞ B. Y. , Güven D. C. , AKTEPE O. H. , Guner G., Taban H., KERTMEN N., ARIK Z., DİZDAR Ö.
44th Congress of the European-Society-for-Medical-Oncology (ESMO), Barcelona, Spain, 27 September - 01 October 2019, vol.30
- III. **Is microsatellite instability a negative prognostic factor in early stage endometrial cancer patients?**
Lacın S., Tasar G. E. , Usubutun A., Arik Z., Karakas Y., Yuce D., Salman M. C. , Kars A.
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 31 May - 04 June 2019, vol.37

- IV. **TRASTUZUMAB KARDİYOTOKSİSİTESİNİ İMMUNGLOBULİN /- STEROİD UYGULAMASI ÖNLEYEBİLİR Mİ?, TAVŞAN MODELİ HAYVAN DENEYİ**
KERTMEN N., AKSOY S., ERMİŞ D. Y. , KESKİN Ö., SOLAK M., ARIK Z., SARICI F., ATEŞ Ö., ALTUNDAĞ M. K.
22. UKK, Turkey, 19 - 23 April 2017
- V. **Cytoreductive surgery for intestinal cancer patients metastatic to the adnexal presenting as primary ovarian cancer.**
Arik Z., Dizdar O., Yildirim M. E. , Ozgu E., Oz M., Terzioglu S. G. , Gungor T.
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, Illinois, United States Of America, 29 May - 02 June 2015, vol.33
- VI. **Which sequence prevents the heart from trastuzumab and anthracycline toxicity: Electron microscopy study in rats**
Aksoy S., Kertmen N., ÜNER A., Sargon M., Ozkayar O., Keskin O., Babacan T., Sarici S. F. , Sendur M. A. N. , Arik Z., et al.
50th Annual Meeting of the American-Society-of-Clinical-Oncology, Illinois, United States Of America, 30 May - 03 June 2014, vol.32
- VII. **Temporal changes in the survival of metastatic renal cell cancer patients and the impact of targeted agents: Single center experience**
Erman M., Arik Z., Kilickap S., Bilen C. Y. , Yazici S., Akdogan B., Ozen H.
Genitourinary Cancers Symposium, San-Francisco, Costa Rica, 30 January - 01 February 2014, vol.32
- VIII. **Arrhythmias during and after zoledronic acid infusion patients with bone metastasis.**
Yazici O., Aksoy S., Ucar O., Ozdemir N., Demir M., Sendur M. A. N. , Arik Z., Yaman S., Eren T., Uncu D., et al.
49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 31 May - 04 June 2013, vol.31
- IX. **Clinicopathologic characteristics of pure papillary breast carcinoma**
Turkoz F. P. , Solak M., Keskin O., Arik Z., Arslan C., Kertmen N., Aksoy S., Altundag K.
49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 31 May - 04 June 2013, vol.31
- X. **Inflammatory markers in metastatic breast cancer.**
Sahin U., Petekkaya H., Gecmez G., Babacan T., Roach E. C. , Sarici S. F. , Arslan C., Arik Z., Aksoy S., Altundag K.
49th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 31 May - 04 June 2013, vol.31
- XI. **Variations of the ER, PR, and HER2 expression status according to operation day in breast cancer patients.**
Arik Z., Aksoy S., Sendur M. A. N. , Yaman S., Altundag K.
48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 1 - 06 June 2012, vol.30
- XII. **Administration of contrast media just before the cisplatin-based chemotherapy increases the cisplatin-induced nephrotoxicity.**
Sendur M. A. N. , Aksoy S., Yaman S., Kos F. T. , Arik Z., Civelek B., Ozdemir N., Uncu D., Zengin N.
48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 1 - 06 June 2012, vol.30
- XIII. **Does total breastfeeding time influence the clinicopathologic characteristics and prognosis in breast cancer patients?**
Yaman S., Aksoy S., Sendur M. A. N. , Arik Z., Ozdemir N., Zengin N., Altundag K.
48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 1 - 06 June 2012, vol.30
- XIV. **Demographic and clinicopathologic characteristics of breast cancer patients with history of oral alendronate use**
Aksoy S., Sendur M. A. N. , Yaman S., Arik Z., Ozdemir N., Zengin N., Altundag K.
48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Illinois, United States Of America, 1 - 06 June 2012, vol.30

June 2012, vol.30

Citations

Total Citations (WOS):126

h-index (WOS):5